Last update 04 Dec 2025

LY-4257496

Overview

Basic Info

Drug Type
Therapeutic radiopharmaceuticals
Synonyms
LY-4257496
Target
GRPR
Action
modulators
Mechanism
GRPR modulators(Gastrin releasing peptide receptor modulators)
Therapeutic Areas
NeoplasmsDigestive System DisordersSkin and Musculoskeletal Diseases+ [1]
Active Indication
Colorectal CancerEndometrial CarcinomaER-positive/HER2-negative Breast Cancer+ [4]
Inactive Indication-
Originator Organization
Eli Lilly & Co.Eli Lilly & Co.
Active Organization
Eli Lilly & Co.Eli Lilly & Co.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with LY-4257496
NCT07114601
/ RecruitingPhase 1
A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)
100 Clinical Results associated with LY-4257496
Login to view more data
100 Translational Medicine associated with LY-4257496
Login to view more data
100 Patents (Medical) associated with LY-4257496
Login to view more data
100 Deals associated with LY-4257496
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colorectal CancerPhase 1
United States
Eli Lilly & Co.Eli Lilly & Co.
06 Aug 2025
Colorectal CancerPhase 1
Canada
Eli Lilly & Co.Eli Lilly & Co.
06 Aug 2025
Colorectal CancerPhase 1
France
Eli Lilly & Co.Eli Lilly & Co.
06 Aug 2025
Colorectal CancerPhase 1
Germany
Eli Lilly & Co.Eli Lilly & Co.
06 Aug 2025
Colorectal CancerPhase 1
Spain
Eli Lilly & Co.Eli Lilly & Co.
06 Aug 2025
Endometrial CarcinomaPhase 1
United States
Eli Lilly & Co.Eli Lilly & Co.
06 Aug 2025
Endometrial CarcinomaPhase 1
Canada
Eli Lilly & Co.Eli Lilly & Co.
06 Aug 2025
Endometrial CarcinomaPhase 1
France
Eli Lilly & Co.Eli Lilly & Co.
06 Aug 2025
Endometrial CarcinomaPhase 1
Germany
Eli Lilly & Co.Eli Lilly & Co.
06 Aug 2025
Endometrial CarcinomaPhase 1
Spain
Eli Lilly & Co.Eli Lilly & Co.
06 Aug 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free